Compare · MDLN vs PEN
MDLN vs PEN
Side-by-side comparison of Medline Inc. (MDLN) and Penumbra Inc. (PEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PEN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 3.7x PEN ($12.78B).
- MDLN has been more active in the news (12 items in the past 4 weeks vs 2 for PEN).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- Penumbra Inc.
- Price
- $35.64+2.77%
- $324.61+0.26%
- Market cap
- $46.86B
- $12.78B
- 1M return
- -10.28%
- -
- 1Y return
- -12.54%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- 2015
- News (4w)
- 12
- 2
- Recent ratings
- 25
- 25
Penumbra Inc.
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
Latest PEN
- President Narayan Shruthi was granted 3,060 shares, increasing direct ownership by 10% to 33,880 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Penumbra Inc.
- SEC Form 10-Q filed by Penumbra Inc.
- Penumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Penumbra, Inc. Reports Second Quarter 2026 Financial Results
- THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
- First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
- Penumbra Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
- Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke